Purinergic receptor P2

**Purinergic receptor P2** refers collectively to two main families of cell surface receptors that detect extracellular nucleotides. These subfamilies are **P2X receptors** (ligand-gated ion channels) and **P2Y receptors** (G protein-coupled receptors), both widely expressed in mammalian tissues. They participate in a broad range of physiological processes, including neurotransmission, hemostasis, immune responses, mechanotransduction, and cell survival. Their dysfunction or overactivation is implicated in diseases such as thrombosis, inflammation, neurodegenerative disorders, certain cancers, and pain syndromes. Several drug classes, especially P2Y12 antagonists like clopidogrel and ticagrelor, are approved for clinical use in preventing thrombosis[5][6]. The term "Purinergic receptor P2" is generic and should be replaced by references to its specific receptor subtypes for meaningful biomedical annotation[1][3][4].\n\n**Caveat:** The term "Purinergic receptor P2" is not itself a recommended canonical entity, as it refers to a receptor family rather than a unique molecular species. For structured data or biomedical research, annotate specific subtypes (e.g., "P2X7 receptor", "P2Y12 receptor").

Other names

P2 receptor familyP2X receptor (subfamily)P2Y receptor (subfamily)P2 nucleotide receptor

Antagonism or inhibition of platelet aggregation (P2Y12); Modulation of immune and inflammatory responses; Modulation of nerve signaling/pain transmission